According to Corcept Therapeutics 's latest financial reports the company's current revenue (TTM) is $0.48 B. In 2022 the company made a revenue of $0.40 B an increase over the years 2021 revenue that were of $0.36 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $0.48 B | 20.04% |
2022 | $0.40 B | 9.8% |
2021 | $0.36 B | 3.42% |
2020 | $0.35 B | 15.46% |
2019 | $0.30 B | 21.99% |
2018 | $0.25 B | 57.82% |
2017 | $0.15 B | 95.77% |
2016 | $81.32 M | 61.72% |
2015 | $50.28 M | 89.39% |
2014 | $26.55 M | 156.37% |
2013 | $10.35 M | 213.18% |
2012 | $3.3 M | |
2011 | N/A | |
2010 | N/A | -100% |
2009 | $0.03 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | $93.02 B | 19,184.17% | ๐บ๐ธ USA |
Novartis NVS | $51.01 B | 10,475.17% | ๐จ๐ญ Switzerland |
Pfizer PFE | $58.49 B | 12,026.87% | ๐บ๐ธ USA |
Eli Lilly LLY | $34.12 B | 6,974.19% | ๐บ๐ธ USA |
Merck MRK | $60.11 B | 12,362.09% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | $45.00 B | 9,230.09% | ๐บ๐ธ USA |
MannKind Corp MNKD | $0.19 B | -58.75% | ๐บ๐ธ USA |
Esperion Therapeutics ESPR | $0.11 B | -75.88% | ๐บ๐ธ USA |
BioMarin Pharmaceutical BMRN | $2.41 B | 401.52% | ๐บ๐ธ USA |